Reactive capillary hemangiomas induced by camrelizumab in a patient with hepatocarcinoma

Xue Zhang^{1

2}, Mengxin Wang^{1

2}, Bingjun Shi¹

Affiliations

¹ Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital (First People's Hospital of Chongqing City), Chongqing, China.
² Guizhou University of Traditional Chinese Medicine, Guiyang, China.

Xue Zhang et al. Int J Dermatol. 2021 Oct.

. 2021 Oct;60(10):e409-e410.

doi: 10.1111/ijd.15606. Epub 2021 May 26.

Xue Zhang^{1

2}, Mengxin Wang^{1

2}, Bingjun Shi¹

¹ Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital (First People's Hospital of Chongqing City), Chongqing, China.
² Guizhou University of Traditional Chinese Medicine, Guiyang, China.

No abstract available

References

1. Wang CY, Sheng CC, Ma GL, et al. Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy. Acta Pharmacol Sin 2020; 5.
1. Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020; 21: 571-580.
1. Wang W, Wu M, Liu M, et al. Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication. J Immunother Cancer 2020; 8: e000793.
1. Dong W, Shasha Z, Pingan D, et al. Immune-related adverse events mimicking Behcet's disease in a gastric cancer patient following camrelizumab treatment. Iran J Immunol 2020; 17: 167-171.
1. Wang F, Qin S, Sun X, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol 2020; 13: 47.